Cambridgeshire and Peterborough
Formulary
 
back
9 Nutrition and blood
09-01-03 Erythropoietin

Darbepoetin Alfa Aranesp®
Restricted

  • CUHFT:

    • Approved in line with NICE TA323 for treating anaemia in people with cancer having chemotherapy.

    • Renal team for renal patients not on haemodialysis.

    • Haematologists for multiple myeloma, to prevent or reduce blood transfusions.

    • As per Trust guideline on refusal of transfusion



  • NWAFT: Restricted to use in renal patients

  • Non-formulary at all other Trusts

Link  CUH Blood and blood products transfusion - Management of patients who refuse - policy
 

Restricted Drug Red Hospital View adult BNF  View SPC online  View childrens BNF  HCD
Epoetin alfa Binocrit®
Restricted

  • CUHFT:


    • Approved in line with NICE TA323 for treating anaemia in people with cancer having chemotherapy.

    • Also used within haematology and renal.

    • If prescribing on the ward, confirm dialysis patients are not already receiving it from the dialysis unit.

    • Chairman's action required for Jehovah's Witnesses treatment of anaemia.


  • Non-formulary at all other Trusts


Restricted Drug Red Hospital View adult BNF  View SPC online  View childrens BNF  HCD
Epoetin alfa Eprex®
Restricted

  • NWAFT: Formulary

  • Non formulary at all other trusts


Restricted Drug Red Hospital View adult BNF  View SPC online  View childrens BNF  HCD
Epoetin beta NeoRecormon®
Restricted

  • CUHFT:

    • Approved in line with NICE TA323 for treating anaemia in people with cancer having chemotherapy.

    • Also used within haematology and renal.

    • Chairman's action required for Jehovah's Witnesses treatment of anaemia.



  • NWAFT: Formulary

  • Non formulary at all other trusts

Link  MHRA Drug Safety Update: Epoetin beta (NeoRecormon) - increased risk of retinopathy in preterm infants cannot be excluded
 

Restricted Drug Red Hospital View adult BNF  View SPC online  View childrens BNF  HCD